Cell Therapy Catapult
5
0
0
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
20.0%
1 terminated/withdrawn out of 5 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
ENgineered Tissue Repair of BronchopleUral FiSTula
Role: collaborator
A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome
Role: collaborator
WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study
Role: collaborator
A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients
Role: collaborator
A Study to Assess the Safety, Tolerability and Potential Efficacy of a Tracheal Replacement Consisting of a Tissue-engineered Tracheal Scaffold With Seeded Mesenchymal Cells
Role: lead
All 5 trials loaded